Insys Theraptcs Cmn (INSY) 14.36 $INSY Insys

New Post Public Reply Private Reply Replies (0) Message Board

Sep 2, 2016 at 7:11 AM

Insys Theraptcs Cmn (INSY) 14.36 $INSY

Insys Therapeutics, Inc. to Present at Morgan Stanley Global Healthcare Conference
GlobeNewswire - Thu Sep 01, 6:00AM CDT
Insys Therapeutics, Inc. ("Insys" or "the Company"

(NASDAQ:INSY) today announced that Darryl Baker, Chief Financial Officer, and Santosh Vetticaden, MD, PhD, Senior Vice President and Chief Medical Officer, will present at the Morgan Stanley Global Healthcare Conference as follows:
INSY: 14.36 (+0.09), MS: 31.91 (-0.15)

Purcell Julie & Lefkowitz LLP Is Investigating Insys Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Tue Aug 30, 7:07AM CDT
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Insys Therapeutics, Inc. (NASDAQ: INSY).
INSY: 14.36 (+0.09)

Covered Call reports for Fitbit, INSYS Therapeutics, eBay, Morgan Stanley and Cisco Systems include trade ideas that offer returns of 20% or more!
PR Newswire - Thu Aug 25, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CSCO, EBAY, FIT, INSY, and MS.
FIT: 14.95 (-0.53), INSY: 14.36 (+0.09), EBAY: 32.13 (-0.03), CSCO: 31.58 (+0.14), MS: 31.91 (-0.15)

Insys Therapeutics Reports Phase 3 Trial of Sublingual Buprenorphine Spray Met Primary Endpoint in Patients with Moderate-to-Severe Postoperative Pain after Bunionectomy
GlobeNewswire - Wed Aug 24, 5:50AM CDT
Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company"

today reported that the Phase 3 trial for the Buprenorphine Sublingual Spray met its primary endpoint.
INSY: 14.36 (+0.09)

Insys Therapeutics Starts Enrollment in Cannabidiol Trial
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 4:32PM CDT
Insys Therapeutics, Inc. (INSY) announced that it has enrolled the first patient in a phase II trial on its pharmaceutical cannabidiol (CBD) product candidate.
INSY: 14.36 (+0.09), GWPH: 82.28 (+0.53), CORT: 5.35 (+0.02), PCRX: 40.37 (+0.74)

Identifying Newest Cannabis Strains for Cancer Treatment and Other Ailments Gain Headway Behind Pharmacological Evaluations
PR Newswire Europe - Wed Aug 10, 7:31AM CDT
CORAL SPRINGS, Florida, August 10, 2016 /PRNewswire/ --
ABT: 42.30 (+0.28), INSY: 14.36 (+0.09), CGC.TO: 3.77 (+0.06), GWPH: 82.28 (+0.53)

Insys Therapeutics Reports Second Quarter 2016 Results
GlobeNewswire - Wed Aug 03, 5:50AM CDT
Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company"

today announced financial results for the three-month period ended June 30, 2016.
INSY: 14.36 (+0.09)

Medical Product Stocks Earnings Preview for Aug 3: BIO, CSII & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:35AM CDT
Medical has been a stand out performer so far in Q2.
MGNX: 30.05 (+0.24), INSY: 14.36 (+0.09), CSII: 24.45 (-0.02), BIO: 149.49 (+0.68), CNAT: 1.86 (+0.05)

What Investors Think of These Biotech Stocks? - Genocea Biosciences, BioDelivery Sciences Intl., INSYS Therapeutics, and Agios Pharma
PR Newswire - Thu Jun 02, 7:20AM CDT
Restructuring activities within the Biotech industry as well as the nearing U.S. presidential election continues to affect the overall condition of firms in this space. But despite the uncertainties, investors see potential growth in select companies that. Today, ActiveWallSt.com reviews the performances of the following equities: Genocea Biosciences Inc. (NASDAQ: GNCA), BioDelivery Sciences International Inc. (NASDAQ: BDSI), INSYS Therapeutics Inc. (NASDAQ: INSY), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Click below to get your complimentary trade alerts:
BDSI: 2.45 (+0.01), INSY: 14.36 (+0.09), AGIO: 36.74 (-0.10), GNCA: 5.28 (-0.08)

Insys Therapeutics, Inc. to Present at Two Upcoming Conferences in June
GlobeNewswire - Thu May 26, 3:30PM CDT
Insys Therapeutics, Inc. ("Insys" or "the Company"

(NASDAQ:INSY) today announced that Darryl Baker, Chief Financial Officer, and Santosh Vetticaden, MD, PhD, Senior Vice President and Chief Medical Officer, will present at two upcoming conferences in June as follows:
INSY: 14.36 (+0.09)

By 2020 Marijuana Sales are Expected to Reach Nearly $23 Billion With Predictions 2016 Will Be the Greenest Year in History; Company Executes International License Agreement
PR Newswire - Wed May 25, 7:30AM CDT
As illustrated by the Spring 2016 Marijuana Business Conference & Expo earlier this month, the numbers and momentum of cannabis in the US are undeniable. As revenues continue to climb into the billions, more research and development push the sector forward.According to the newly released 4th Edition State of Legal Marijuana Markets Report from from ArcView Market Research and New Frontier, a cannabis-focused data-analysis firm, much of the increase in sector is attributed to adult use market sales, which hit $1.3 billion last year alone. By 2020, adult use and medical marijuana sales are expected to reach nearly $23 billion.
INSY: 14.36 (+0.09), GWPH: 82.28 (+0.53)

Insys Therapeutics Successfully Completes Safety and Pharmacokinetic (PK) Study of Cannabidiol Oral Solution in Pediatric Epilepsy Patients
GlobeNewswire - Tue May 24, 5:50AM CDT
Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company"

today announced that it has successfully completed its Phase 1/Phase 2 safety and pharmacokinetic (PK) study in pediatric subjects with treatment-resistant epilepsy.
INSY: 14.36 (+0.09)

Repros Announces the Appointment of Mr. Patrick Fourteau as Chairman of the Board
GlobeNewswire - Mon May 16, 3:00PM CDT
Repros Therapeutics Inc. (Nasdaq:RPRX) today announced that it has appointed Mr. Patrick Fourteau to its Board of Directors, where he will serve as Chairman of the Board.
INSY: 14.36 (+0.09), RPRX: 2.00 (-0.03)

Insys Therapeutics beats Street 1Q forecasts
Automated Insights - Thu Apr 28, 9:36AM CDT
CHANDLER, Ariz. (AP) _ Insys Therapeutics Inc. (INSY) on Thursday reported first-quarter net income of $2.4 million.
INSY: 14.36 (+0.09)

Insys Therapeutics Reports First Quarter 2016 Results
GlobeNewswire - Thu Apr 28, 5:50AM CDT
Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company"

today announced financial results for the three-month period ended March 31, 2016.
INSY: 14.36 (+0.09)

Insys Therapeutics, Inc. to Present at Deutsche Bank 41st Annual Health Care Conference
GlobeNewswire - Tue Apr 26, 3:30PM CDT
Insys Therapeutics, Inc. ("Insys" or "the Company"

(NASDAQ:INSY) today announced that Darryl Baker, Chief Financial Officer, and Santosh Vetticaden, MD, PhD, Senior Vice President and Chief Medical Officer, will present at the Deutsche Bank 41 Annual Health Care Conference as follows:
INSY: 14.36 (+0.09), DB: 14.69 (-0.06)

Don't Get Smoked by These Pot Stocks on 4/20
David Bartosiak - Zacks Investment Research - Wed Apr 20, 3:45PM CDT
Pot is still illegal at the Federal level but there are some medicinal marijuana companies worth looking at
CARA: 5.38 (-0.04), JNJ: 119.08 (-0.26), INSY: 14.36 (+0.09), GWPH: 82.28 (+0.53), YUM: 90.76 (+0.05), PEP: 107.29 (+0.54)

What Falling Estimates & Price Mean for INSYS Therapeutics (INSY)
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 4:59PM CDT
INSYS Therapeutics has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off.
INSY: 14.36 (+0.09), ATRC: 15.50 (+0.11)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Machine Grabs Prime Dallas Property Amid Apartment Boom

Dallas' Hot Market and Machine's Bold Move Well, well, looks like Machine Investment Group's been busy flexing its real estate muscles, bagging a 490-unit gem in North Dallas—your typical, no-frills off-market grab. We’re talking 75 West, nestled in a juicy infill spot, and it’s catching eyes like gold dust in a pan. You don't need me to tell you North Dallas ain't...

Anecdotes by Artists Brings Raw Scent Stories to Sephora

When Maesa pulls back the curtain, they don't just crack it open—they fling it aside with flair. That's precisely what they're doing with their latest venture, Anecdotes by Artists, a fragrance brand that's taking its first bow exclusively at Sephora. It's not your average perfume launch; it's about the stories behind the scents and the artists who craft them. Unveiling...

Succession Planning in Turmoil: Only 42% Ready

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

Cracking the Code of America's Delivery Addiction

America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...

FutureVault's AI Agents: Transforming Financial Workflows

Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...

Leapora's Taskeen: Redefining Task Accountability

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

Davos Healthcare Aims to Revolutionize Hospital Ratings

Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...

Dr. Desi Bartlett Teams Up with Glo for Perimenopause Focus

Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...

FJBio Boosts Antibody Discovery with Sapio AI

In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...

K-Beauty Takes Front Stage at Target Beauty Studio

Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...